RT Journal Article
SR Electronic
T1 Validation of a Trans-Ancestry Polygenic Risk Score for Type 2 Diabetes in Diverse Populations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.11.21263413
DO 10.1101/2021.09.11.21263413
A1 Ge, Tian
A1 Patki, Amit
A1 Srinivasasainagendra, Vinodh
A1 Lin, Yen-Feng
A1 Irvin, Marguerite Ryan
A1 Tiwari, Hemant K.
A1 Armstrong, Nicole
A1 Davis, Brittney H.
A1 Perez, Emma
A1 Gainer, Vivian
A1 Benoit, Barbara
A1 O’Connor, Mark J.
A1 Narayan, Renuka
A1 Etheridge, Bethany
A1 Stamou, Maria
A1 Leong, Aaron
A1 Udler, Miriam S.
A1 Choi, Karmel W.
A1 Miles, Ayme D.
A1 Kiryluk, Krzysztof
A1 Khan, Atlas
A1 Chen, Chia-Yen
A1 Feng, Yen-Chen Anne
A1 Huang, Hailiang
A1 Cimino, James J.
A1 Murphy, Shawn
A1 Weiss, Scott T.
A1 Lange, Christoph
A1 Ng, Maggie C. Y.
A1 Smoller, Jordan W.
A1 Lebo, Matthew S.
A1 Meigs, James B.
A1 Limdi, Nita A.
A1 Karlson, Elizabeth W.
YR 2021
UL http://medrxiv.org/content/early/2021/09/15/2021.09.11.21263413.abstract
AB Type 2 diabetes (T2D) is a worldwide scourge caused by both genetic and environmental risk factors that disproportionately afflicts communities of color. Leveraging existing large-scale genome-wide association studies (GWAS), polygenic risk scores (PRS) have shown promise to complement established clinical risk factors and intervention paradigms, and improve early diagnosis and prevention of T2D. However, to date, T2D PRS have been most widely developed and validated in individuals of European descent. Comprehensive assessment of T2D PRS in non-European populations is critical for an equitable deployment of PRS to clinical practice that benefits global populations. Here we integrate T2D GWAS in European, African American and East Asian populations to construct a trans-ancestry T2D PRS using a newly developed Bayesian polygenic modeling method, and evaluate the PRS in the multi-ethnic eMERGE study, four African American cohorts, and the Taiwan Biobank. The trans-ancestry PRS was significantly associated with T2D status across the ancestral groups examined, and the top 2% of the PRS distribution can identify individuals with an approximately 2.5-4.5 fold of increase in T2D risk, suggesting the potential of using the trans-ancestry PRS as a meaningful index of risk among diverse patients in clinical settings. Our efforts represent the first step towards the implementation of the T2D PRS into routine healthcare.Competing Interest StatementDr. Choi is involved in the Genetics and Neuroscience Special Interest Group and the Anxiety & Depression Association of America. Dr. Kiryluk serves on the Scientific Advisory Board for Gilead Sciences and Goldfinch Bio. Dr. Chen is an employee of Biogen, Inc. Dr. Weiss has received compensation from UpToDate. Dr. Smoller is a member of the Leon Levy Foundation Neuroscience Advisory Board, participates on the Data and Safety Monitoring Board (DSMB) for the Implementing Genomics in Practice (IGNITE II) program, and received an honorarium for an internal seminar at Biogen, Inc. Dr. Meigs is an Academic Associate with Quest Diagnostics R&D.Funding StatementThe eMERGE Network was initiated and funded by National Human Genome Research Institute (NHGRI) through the following grants: U01HG006828 (Cincinnati Children's Hospital Medical Center and Boston Children's Hospital); U01HG006830 (Children's Hospital of Philadelphia); U01HG006389 (Essentia Institute of Rural Health, Marshfield Clinic Research Foundation, and Pennsylvania State University); U01HG006382 (Geisinger Clinic); U01HG006375 (Group Health Cooperative and the University of Washington); U01HG006379 (Mayo Clinic); U01HG006380 (Icahn School of Medicine at Mount Sinai); U01HG006388 (Northwestern University); U01HG006378 (Vanderbilt University Medical Center); and U01HG006385 (Vanderbilt University Medical Center serving as the Coordinating Center). The eMERGE IV Mass General Brigham site was funded by the NHGRI through U01HG008685, the Columbia University site was funded through U01HG008680, and the University of Alabama site was funded through U01HG011167. This work was additionally supported by the following NIH grants: UL1TR001873, OT2OD026553, OT2HL161841, P30AR070253, P30AR069625, R01DK078616 (J.B.M.), R01HL151855 (J.B.M.), R01HL092173 (N.A.L.), R01AR063759 (E.W.K.), R21AR078339 (E.W.K), K25DK128563 (A.K.), K23DK114551 (M.S.U).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The eMERGE Network was initiated and funded by the National Institutes of Health (NIH). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. The use of eMERGE data in the present work was approved by the Institutional Review Board (IRB) at Mass General Brigham (Protocol 2020P000575). Participants in the four African American cohorts from University of Alabama at Birmingham (UAB) provided consent for genetic research related to cardiovascular diseases. Generation of the GWAS data was funded through the National Heart, Lung, and Blood Institute (NHLBI). The use of the data data for PRS validation was approved by the UAB IRB (REGARDS IRB: 161228001, GenHAT IRB: 160415008, HyperGEN IRB: 160331004, WPC IRB: 131122001). Collection of the Taiwan Biobank (TWB) data was approved by the Ethics and Governance Council (EGC) of TWB and the Department of Health and Welfare, Taiwan (Wei-Shu-I-Tzu NO.1010267471). TWB obtained informed consent from all participants for research use of collected data. The access to and the use of TWB data in the present work was approved by the EGC of TWB (Approval Number: TWBR10907-05) and the Institutional Review Board (IRB) of National Health Research Institutes, Taiwan (Approval Number: EC1090402-E).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGWAS summary statistics from the Mahajan et al. 2018 study are publicly available at the DIAGRAM consortium website (http://diagram-consortium.org). Biobank Japan (BBJ) GWAS summary statistics are publicly available on the BBJ website (https://pheweb.jp). GWAS summary statistics from the Ng et al. 2014 study were obtained through a collaboration with Dr. Ng. The eMERGE genotype data are deposited in dbGaP (Study Accession: phs001584.v2.p2). Other individual-level datasets analyzed in the present study are not publicly available under current IRB protocols, but are available through authorized collaborations.